Subscribe
shutterstock_1667502061_tada_images
Tada Images / Shutterstock.com
2 February 2021Big PharmaJeffrey D Morton, Zachary Schroeder and Ryan D Ricks

The importance of Minerva Surgical v Hologic

On January 8, 2021, the US Supreme Court agreed to hear Minerva Surgical v Hologic to consider whether an inventor or those in privity with the inventor may assert patent invalidity as a defence against a patent infringement suit for the inventor’s patent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Breaking: SCOTUS says inventors can challenge their patents, but imposes limits
29 June 2021   The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Big Pharma
Minerva: less risk for inventors, more work for the courts
1 July 2021   The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Medtech
Fed Circuit rejects Minerva patent invalidation bid
12 August 2022   Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Breaking: SCOTUS says inventors can challenge their patents, but imposes limits
29 June 2021   The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Big Pharma
Minerva: less risk for inventors, more work for the courts
1 July 2021   The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Medtech
Fed Circuit rejects Minerva patent invalidation bid
12 August 2022   Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.

More on this story

Americas
Breaking: SCOTUS says inventors can challenge their patents, but imposes limits
29 June 2021   The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope.
Big Pharma
Minerva: less risk for inventors, more work for the courts
1 July 2021   The US Supreme Court opinion in Minverva v Hologic means that inventors will now have a far narrower scope to be able to challenge the validity of their own patents in defence proceedings—a decision that was controversial among the judges.
Medtech
Fed Circuit rejects Minerva patent invalidation bid
12 August 2022   Hologic patent invented by Minerva’s founder cannot be invalidated | Patent in dispute concerns device used to treat uterine bleeding | US Court of Appeals.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
Sandoz wins $137.2m payout for lost profits in generic launch
Dexcom suffers second patent revocation at hands of UPC
Sanofi signs global rights deal to develop rare cancer therapy
WBD to merge with firm to create ‘powerhouse’ practice
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
AstraZeneca unit draws line under Samsung dispute